FDA Puts Clinical Holds on “Off-the-Shelf” CAR-T Trials – OncLive
OncLive |
FDA Puts Clinical Holds on "Off-the-Shelf" CAR–T Trials
OncLive Following the death of a 78-year-old man being treated for blastic plasmacytoid dendritic cell neoplasm (BPDCN), the FDA placed clinical holds on 2 phase I trials investigating a gene-edited allogeneic CAR T-cell (UCART) therapy known as UCART123. FDA hits Cellectis' off-the-shelf CAR-T program with clinical hold … Patient Death Triggers FDA Hold For Cellectis's “Off the Shelf” CAR–T Genetically Modified Immune Cells Have Killed a Patient, Halting Two Cutting-Edge Trials |
